The processability of the veterinary API across tablet, capsule, injection, powder, granule, premix, and solution lines is governed by four physical attributes: particle size distribution, bulk density, moisture sorption isotherm, and polymorph stability in aqueous media. A single API lot is rarely acceptable for all downstream uses without defined rework, because a micronized lot with d90 ≤ 10 µm is needed for otic suspensions, while a direct compression tableting lot may tolerate d90 up to 25 µm if flow and segregation are controlled. Each application below is therefore presented with the unit operation, critical threshold, release method, and terminal packaging configuration that apply to production-scale veterinary manufacturing.

Direct Compression of Low-Dose Veterinary Tablets: Segregation Risk and Weight Uniformity Windows

The API is milled to a particle size d90 ≤ 20 µm as determined by laser diffraction according to USP <429> / Ph. Eur. 2.9.31 before direct compression. Tablet batches containing 5 mg active ingredient per unit are blended with spray-dried lactose monohydrate, microcrystalline cellulose type 102, crospovidone, and magnesium stearate in an 800 L bin blender at 12 rpm for 25 minutes. The primary process conflict is segregation during discharge; if the API bulk density falls below 0.35 g/cm³ or the particle size distribution span exceeds 2.0, segregation is observed after more than 15 minutes of blend storage. Tablet press speed is maintained between 25,000 and 45,000 tablets per hour on a rotary press with D-tooling, with precompression force at 2.5–4.0 kN and main compression force at 8–14 kN to achieve hardness of 60–90 N. Weight uniformity is monitored using USP <905> Uniformity of Dosage Units; the acceptance value must not exceed 15.0 for tablets. Disintegration is tested per USP <701> and must be ≤ 15 minutes in 37 °C purified water. The terminal product is a non-sterile oral veterinary tablet packaged in PVC/aluminium blister packs with desiccant when the packaging suite relative humidity exceeds 40%.

For wet granulation lines, the API is granulated with 5% w/w povidone K30 solution at a binder addition level of 8–12% w/w dry mass using a high-shear mixer with chopper at 1,500 rpm and impeller at 300 rpm. The endpoint is determined by torque rise and granule median particle size d50 150–250 µm; overdrying below 1.0% loss on drying causes friability on compression, while moisture above 2.5% triggers sticking on punches. The dried granules are milled through a 1.0 mm screen and lubricated with 0.5% magnesium stearate for 3 minutes total blend time; longer lubrication reduces tablet tensile strength. Release testing includes assay by HPLC with acceptance 95.0–105.0% and related substances per Ph. Eur. 2.2.29. The process is limited to API lots with water activity below 0.5 when direct compression is used, because higher water activity accelerates ester or amide hydrolysis in the blend during hold times longer than 48 hours.

When Terminal Moist Heat Sterilization Is Not Feasible for Thermolabile Veterinary Injections

For injectable solutions, the API is dissolved in Water for Injection at 10–20 °C under nitrogen blanketing to prevent oxidation. A 0.2 µm polyethersulfone filter is used for aseptic filtration when the API degrades above 80 °C or when solution pH drift exceeds 0.3 units during 121 °C autoclaving. The filtered solution is filled into amber Type I glass vials or cyclic olefin copolymer syringes in an ISO 14644-1 Class 7 background with a Class 5 local zone. Sterility assurance relies on USP <71> sterility testing and USP <85> bacterial endotoxins testing, with endotoxin acceptance calculated from the parenteral dose per kilogram; for a 1 mg/kg dose, the limit is typically ≤ 0.5 EU/mg unless the monograph specifies otherwise. Tonicity is adjusted with sodium chloride to 280–320 mOsm/kg and pH is adjusted with hydrochloric acid or sodium hydroxide to 5.5–7.0. The terminal product is a sterile injection in strengths from 2 to 10 mg/mL, administered intramuscularly or subcutaneously. Multidose vials contain 1.0% w/v benzyl alcohol as preservative, and preservative efficacy is tested per USP <51>.

If terminal sterilization is possible, filled vials are autoclaved with a process having an F0 value ≥ 15 minutes at 121 °C and 1.05 bar pressure. The critical load-dependent variable is residual air removal in porous load cycles; air pockets in chilled vials reduce the measured F0 by up to 2 minutes and must be eliminated by vacuum pulsing. After sterilization, leachables from rubber stoppers are controlled under USP <381> for elastomeric closures for injections. Filtration integrity is verified by bubble point testing before and after filtration; because the API can lower surface tension, the bubble point value is individually determined on the actual solution, not on water alone.

Hard capsule manufacturing with this API is constrained by flow properties rather than chemical stability. Before encapsulation, the API is blended with pregelatinized starch, colloidal silicon dioxide at 0.2% w/w, and sodium stearyl fumarate in a diffusion mixer for 20 minutes. The target blend has a Carr index below 25 and Hausner ratio below 1.25; values above these thresholds trigger weight variability across capsule size 0 at filling speeds above 40,000 capsules per hour. On dosator-type machines, powder bed height is maintained at 60–80% of hopper level to keep fill weight RSD below 3.0%. Fill weight is verified according to Ph. Eur. 2.9.5 mass uniformity of single-dose preparations; capsules with fill weight 150 mg at 10 mg API strength must meet acceptance value ≤ 15. Dissolution testing uses USP <711> Apparatus II with 900 mL 0.1 M HCl at 37 °C and 50 rpm; Q ≥ 75% at 45 minutes is typically required for immediate-release veterinary capsules. The terminal product is a hard gelatin or HPMC capsule packed in HDPE bottles with a desiccant canister; capsules must not be split or crushed at the end-user level unless a feed stability study has demonstrated acceptable potency for 2 hours in feed.

Low-dose capsule blends containing less than 1% API are prepared by geometric dilution, starting with 1 part API to 3 parts carrier passed through a 500 µm screen, then scaling to the final batch size in a 600 L V-blender. The main failure mode is blend segregation after discharge; transfer into the hopper therefore uses gravity at minimal drop height, and the hopper is not vibrated. The final product is tested for content uniformity per USP <905> with acceptance value ≤ 15.0 and for water content by USP <921> Karl Fischer with limit ≤ 3.0% for hard shells. For capsule lines handling low API mass fractions, bowl lift height and feed frame speed must be locked separately for each batch; a feed frame speed above 30 rpm increases fill weight variability in formulations with low cohesiveness.

What Limits Blend Uniformity in Sachet Granules Below 0.5 g Fill Weight?

The API is wet-granulated with lactose monohydrate and hypromellose 3 mPa·s as binder. The binder solution is sprayed at 10% w/w dry mass over 5 minutes in a fluid-bed granulator with inlet air temperature 60 °C and product temperature 30–35 °C. Granules are dried to loss on drying 1.0–2.0% and sieved through 0.8 mm. Fines below 75 µm are limited to ≤ 20% because API-rich fines migrate to the bottom of the sachet filling auger and create superpotent units. Sachet fill weight 0.5 g at active 25 mg is filled on vertical form-fill-seal machines with auger fillers; fill weight RSD must remain below 2.5%. The terminal product is a single-dose oral powder for reconstitution in drinking water for pigs or poultry. Uniformity of mass is tested per Ph. Eur. 2.9.5; ordinary oral powders are generally not dissolution tested, but dispersibility is evaluated by dispersing one sachet in 200 mL water at 25 °C with stirring at 150 rpm. Complete dispersion must occur within 60 seconds.

The critical process conflict is moisture sorption during sachet sealing. If the product temperature drops below the dew point, the granules absorb moisture, which increases cohesion and causes bridging in the auger. This is avoided by keeping the packaging suite at ≤ 35% relative humidity and granule temperature 2–5 °C above the suite dew point. The finished sachet is sealed with a moisture barrier laminate of polyethylene, aluminium foil, and polyester. Stability is assigned under ICH Q1A(R2) for veterinary medicinal products, with photostability evaluated per ICH Q1B. The product is not suitable for dry mixing into feed at the farm because the sachet powder is not designed as a premix; its cohesive granule structure resists uniform distribution in large feed volumes.

Premix operations for this API require geometric dilution into feed-grade carriers before the API is distributed across a ribbon blender. A representative line uses 1 part API blended with 9 parts light mineral oil wetting agent and 90 parts calcium carbonate carrier in a 100 kg high-shear mixer for 10 minutes at 200 rpm, then transfers this intermediate to 1,000 kg of the final feed carrier. The final premix is mixed in a single-ribbon blender at 20 rpm for 20 minutes; mix uniformity is tested by collecting three replicate samples from ten positions and assaying the API by HPLC. The release criterion is a coefficient of variation ≤ 5.0% for all samples and the mean assay within 90.0–110.0% of label claim. The terminal product is a medicated premix for swine or poultry feed, included at 0.5–5.0 kg per tonne of complete feed. Compliance is governed by EU Regulation 2019/4 for medicated feed and by local GMP codes for veterinary premix production. Critical operational limit: carrier moisture above 6.0% causes API hydrolysis during storage at 30 °C; therefore the final premix is packed in woven polypropylene bags with an inner polyethylene liner and stored below 25 °C.

If the API is supplied as a spray-dried dispersion rather than micronized powder, direct blending with calcium carbonate is possible only if the carrier particle size d50 is 75–150 µm and the angle of repose is below 40°. When the carrier contains fines above 20%, published segregation data for this specific API-carrier pairing is limited; transport simulation sampling is used instead of assuming that mixer discharge data predicts bag-level uniformity. Feeding levels are confirmed by analyzing complete feed collected at the mixer discharge and after 2 minutes in a screw conveyor. The API assay method is validated over the range 50–150% of premix label claim per USP <1225>, and the sample extraction must include a wetting step with surfactant to release API from oil-coated carrier surfaces.

Otic Suspension Wetting and Preservative Efficacy Boundaries

For ear drops, the API is formulated as a sterile suspension when the drug is practically insoluble in aqueous buffers. The API is first wet with polysorbate 80 at 0.5% w/w and glycerin, then dispersed in a vehicle containing carbomer 940 or hypromellose. The target suspension has pH 5.0–7.0, osmolality 250–350 mOsm/kg, and viscosity 15–50 mPa·s at 20 °C measured by rotational viscometer spindle 63 at 60 rpm. Terminal sterilization may not be possible for all polymer-containing vehicles; therefore the vehicle is sterilized at 121 °C for 15 minutes and the API is added aseptically through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade filter if soluble, or the API is sterilized by gamma irradiation at 25 kGy before dispersion. Sterility is tested per USP <71>, and preservative efficacy is evaluated per USP <51> with challenge organisms including Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans. The terminal product is a multi-dose otic suspension packaged in low-density polyethylene dropper bottles with a sealed tip cap.

Particle size control is overriding: d90 must be ≤ 10 µm for otic suspension, while d50 2–5 µm is preferred to avoid caking. If the API is not fully wetted, agglomerates form within 24 hours and redispersibility fails after 30 seconds of vigorous shaking. The release test includes settled bed volume ratio and particle size distribution by laser diffraction per USP <429>. The dropper delivers 0.2 mL per squeeze; dose uniformity is verified by delivering ten drops into tared beakers and measuring mass. Because this is the raw material’s origin dosage form, the same API lot can be used for otic and other dosage forms only if microbial burden and particle size are separately controlled; the sterile otic grade demands endotoxin ≤ 0.5 EU/mL and bioburden ≤ 10 CFU/g before sterilization.

Oral drench solutions are prepared at active concentrations from 1 to 20 mg/mL using Water for Injection or purified water, propylene glycol 10–30% w/w, and sodium benzoate 0.2% w/w. The solubility of the API is pH-dependent; solubility is determined in triplicate at 20 °C and 40 °C over the pH range 3.0–7.0 with phosphate, citrate, and acetate buffers at constant ionic strength 0.1 M. If the API transforms to a less soluble hydrate above pH 6.5, the formulation is maintained at pH 4.0–5.5 to avoid precipitation. Light exposure triggers degradation of unprotected solutions; therefore amber polyethylene terephthalate bottles or coloured high-density polyethylene containers are required, and photostability is tested per ICH Q1B. The terminal product is a ready-to-use oral drench for cattle, sheep, or pigs, typically delivered with a 0.5–5 mL graduated syringe. The acceptance criteria include assay by HPLC 95.0–105.0%, pH stability within ±0.3 units over shelf life, and preservative effectiveness per USP <51>.

During batch manufacture, the API is added to 80% of the final volume of vehicle under continuous mixing at 250 rpm; propylene glycol is pre-blended with the API to form a slurry before aqueous dilution to prevent floating of hydrophobic particles. If the solution is filled by peristaltic pump at 30–60 bottles per minute, the pump tubing is selected from platinum-cured silicone with low leachables; spallation risk is controlled by monitoring fill volume with in-line checkweighers and rejecting units outside ±5.0% of target. The solution is not sterile, but bioburden limits are applied at ≤ 100 CFU/mL and absence of Escherichia coli in 1 mL per USP <62>. The drench is not suitable for intravenous injection; differentiation of packaging and labeling is required to prevent route-of-administration errors in mixed-flock veterinary settings.